The purpose of this study is to evaluate the immunogenicity and safety of an inactivated, non adjuvanted A(H1N1)v influenza vaccine in 120 pregnant women.

Study procedures will include 2 doses of vaccine, blood samples, cord blood samples at delivery and recording temperature and vaccine side effects in a memory aid for 7 days following each vaccination. Participants will be involved in study related procedures about 3 at 5 months.

Inclusion Criteria:

• 18 years to 45 years
• Pregnancy between 22 and 32 weeks of gestation
• Provides written informed consent
• Covered by French Social Security

Exclusion Criteria:

• Allergy to eggs or other components in the vaccine
• History of severe reactions following previous influenza vaccines
• H1N1 influenza (virologically documented) during the last 6 months
• Febrile episode within one week prior to vaccination
• Known HIV, HBV, HCV infection
• Multiple sclerosis
• History of Guillain-Barré syndrome
• Organ transplant recipient
• Neoplastic disease in the past 3 years
• Other vaccine within 3 weeks prior to study entry or planned within the month following the last injection
• Systemic corticosteroids,immunotherapy,chemotherapy
• Anticoagulant treatment
• Immunoglobulin or blood transfusion within the 3 months prior to enrollment in this study
• History of cardiac disease
• Chronic liver disease
• Diabetes before pregnancy
• History of premature delivery
• History of eclampsia
• Fetal morphologic abnormalities